Who owns vyvanse

These risks and uncertainties include: those discussed and identified in the New River Pharmaceuticals Inc. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof. New River Pharmaceuticals does not undertake any obligation to republish revised forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Readers are also urged to carefully review and consider the various disclosures in New River Pharmaceuticals' annual report on Form K, filed with the SEC on March 15, , as well as other public filings with the SEC. Shire plc Shire's strategic goal is to become the leading specialty pharmaceutical company that focuses on meeting the needs of the specialist physician.

The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results.

Shire's focused strategy is to develop and market products for specialty physicians. Shire's in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.

For further information on Shire, please visit the Company's website: www. Statements included herein that are not historical facts are forward-looking statements. Britain's third biggest drugs company hopes to replace it with Vyvanse, which has had an "approvable" letter from the US Food and Drugs Administration and could be on the market next year.

Shire and New River teamed up to collaborate on Vyvanse in Shire's chief executive, Matthew Emmens, said the takeover would mean complete ownership of the drug: "Having full control means we can do it our way. That turned out not to be true. It turned out that kids could abuse the drugs, and were doing so. Government prosecutors also alleged that Shire made unsubstantiated suggestions that treatment with Adderall XR would help prevent certain issues linked to ADHD, such as poor academic performance, loss of employment, criminal behavior, traffic accidents, and sexually transmitted disease.

Additionally, the settlement resolves allegations that from April to September , Shire representatives improperly marketed Daytrana, an ADHD patch, as less abuseable than traditional, pill-based medications, and, for part of this period, improperly made phone calls and drafted letters to state Medicaid authorities to assist physicians with the prior authorization process for prescriptions to induce these physicians to prescribe Daytrana and Vyvanse.

Shire cooperated throughout this investigation and, in advance of this settlement, began to correct its marketing activities. Attorney Zachary T. Even Vyvance's marketing chief, Mike Boken , is impressive -- he's seven feet tall! So things look good for Vyvanse Shire's official position is that not only will generic Adderall have no effect on sales of Vyvanse, but that Vyvanse will continue to grow after the deadline.

Take Sanofi-Aventis ' Ambien , which was one of the best-managed generic collapses of recent years. In its heyday, Ambien was 40 percent of scrips written. It is now close to zero. At the same time, generic zolpidem went from zero to more than 50 percent of the market -- more dominant than Ambien was in its prime.